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Abstract
Among several types of tumor, lung cancer is considered one of the most fatal and still the main cause of cancer-
related deaths. Although chemotherapeutic agents can improve survival and quality of life compared with
symptomatic treatment, cancers usually still progress after chemotherapy and are often aggravated by serious side
effects. In the last few years there has been a growing interest in immunotherapy for lung cancer based on
promising preliminary results in achieving meaningful and durable treatments responses with minimal manageable
toxicity. This article is divided into two parts, the first part discusses the role of human immune system in
controlling and eradicating cancer and the mechanisms of immune response evasion by tumor. The second part
reviews the recent progress made in immunotherapy for lung cancer with results from trials evaluating therapeutic
vaccines in addition to immune checkpoint blockade, specifically cytotoxic T lymphocyte associated protein 4,
programmed death receptor 1 pathway, using monoclonal antibodies.
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Background
Lung cancer is the leading cause of cancer death and the
second most common cancer in the world. According to
2012 GLOBOCAN estimation, the total number of lung
cancer new cases was about 1.8 million worldwide. In
China, 652842 new cases were recorded in 2012 compared
with 733280 new cases in 2015 [1]. For years the standard
treatment strategies of lung cancer have been surgery,
chemotherapy, radiation therapy and targeted therapy [2].
Recently, tumor immunotherapy is attracting the most at-
tention among different therapeutic options for treatment
of lung cancer.
Cancer immunotherapy is a type of cancer treatment
designed to boost the body’s natural defenses against
cancer. It is divided into two categories, passive and active
immunotherapy. Passive immunotherapy is defined as an
administration of agents such as monoclonal antibodies or
adaptive cell therapy that directly target tumor [3, 4].
Whereas, active immunotherapy aims to stimulate the
hosts own immune system to eradicate cancer depending
on vaccination with tumor antigens, non-specific immu-
nomodulation using bacterial products, or targeting nega-
tive regulatory receptors that prevent the development of
the tumor immune response [5]. Finally, it should be
noted that efficient tumor immunotherapy must induce a
potent anti-tumor immune response and overcome the ef-
fect of tumor immunosuppression [6].
Cancer immunology
Both innate immunity (Fig. 1) and adaptive immunity
(Fig. 2) play a crucial role in antitumor immune
response. Innate immunity is composed of macrophages,
granulocytes, mast cells, DCs and natural killer (NK)
cells. Whereas, adaptive immunity is composed of B
cells, CD8+ cytotoxic lymphocytes (CTLs) and CD4+
helper T cells. It must be mentioned that NK cells and
ɣδ T cells play at the interface between innate and adap-
tive immunity [7, 8]. The roles of innate and adaptive im-
munity in controlling and eradicating cancers are discussed
below.
CTLs are considered the backbone of immune re-
sponse against tumor. Several studies have reported that
tumor-infiltrating lymphocytes TILs (mononuclear cells
derived from the inflammatory infiltrate in human solid
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Fig. 1 A schematic representation of the role of innate immune cell subsets in tumor immunity. Blue arrows represent the anti-tumor action, Red arrows
represent the inhibition of anti-tumor immunity. TAM: Tumor Associated Macrophages, M1: Classically Activated Macrophages, M2: Alternatively Activated
Macrophages, NK: Natural Killer cells, CTL: Cytotoxic Lymphocytes, VEGF: Vascular Endothelial Growth Factor, GM-CSF: Granulocyte-Macrophage Colony-
Stimulating Factor, M-CSF: Macrophage Colony-Stimulating Factor, TGF-β: Transforming Growth Factor-Beta, Ab: Antibody. Note: T and B cells are related to
the adaptive immune response
Fig. 2 A schematic representation of the role of adaptive immune cell subsets in tumor immunity. Blue arrows represent the anti-tumor action,
Red arrows represent the inhibition of anti-tumor immunity. TNF-α: Tumor necrosis factor alpha, IFN-ɣ: Interferon gamma, CTLs: CD8+ cytotoxic
lymphocytes, TGF-β: Transforming growth factor beta, MDSC: Myeloid-derived suppressor cells
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tumors) contain an abundant level of CTLs with an
ability to invade tumor cells which they were derived.
Recognition of tumor antigen by specific T cells is a
necessary prerequisite for the induction of effective antitu-
mor immune response [9–11]. Tumor antigen presenta-
tion might be mediated by tumor cells in tumor draining
lymph nodes (direct presentation) or via cross-
presentation by pAPC [12]. Cross priming of naïve CD8+
T cells by pAPC invokes a program leading to tumor spe-
cific CTLs which proliferate and traffic to the tumor site
where they ultimately attack and destroy tumor cells [13].
CTLs use various mechanisms to kill tumor cells through
granzymes, perforin [14–16], and ligands of the tumor ne-
crosis factor (TNF) superfamily such as Fas ligand [17].
The anti-tumor effect is also achieved by secretion of
Interferon gamma (IFN-ɣ) [18] and TNF alpha (TNF-α)
[19] from activated CD8+ T cells.
Understanding the importance role of CD4+ T cells in
the antitumor immune response has grown dramatically
over the past decade. Upon encountering antigens and
adequate co-stimulation signals, naive CD4+ T cells are
activated, polarized, and differentiated into distinct sub-
sets including Th1, Th2 [20], Tregs [21], Th17, [22], Th9
[23], Th22 [24] and follicular helper T cells (TFH) [25].
Among these various CD4+ T cells subpopulations, Th1
subset plays a clear antitumor role by coordinating cell-
mediated immunity against cancer cells [26]. First and
foremost, Th1 cells, by producing large amounts of
IFN-ɣ and chemokines, enhance the expansion, priming
and infiltration of CD8+ T cells into the tumor site
[27]. Importantly, The IFN-ɣ which secreted by Th1 cells
exerts anti-proliferative, pro-apoptotic actions and inhibit
angiogenesis in tumor cells in a CD8+ T cells-independent
manner [28]. Th1 cells also recruit and activate inflamma-
tory cells (macrophages, granulocytes, eosinophils and NK
cells) in around the tumor [29]. Indeed, Th1 cells can kill
MHC-II+ tumor cells directly through perforine and
granzyme, TNF-related apoptosis inducing ligand (TRAIL)
receptor and Fas/Fas ligand pathways [30].
NK cells have been gaining importance in recent years
as an efficient approach in cancer immunotherapy.
These cells are able to clear tumor cells directly through
several mechanisms. NK cells induce the tumor cell
apoptosis by 1) secretion of cytoplasmic granules,
perforin and granzymes [31], 2) expression of death
receptor-mediated apoptosis [32] or 3) secretion of
TNF-α [33] and destroying tumor cells through antibody
dependent cellular cytotoxicity by expressing CD16 [34].
Furthermore, NK cells have an indirect antitumor activ-
ity through producing cytokines, chemokines and
growth factors [35]. The IFN-ɣ which produced by NK
cells is responsible for induction of CD8+ T cells to
become CTLs as well as differentiation of CD4+ T cells to-
ward a Th1 response [36]. NK cells also induce
inflammatory responses; modulate monocyte, DC, granulo-
cyte growth and differentiation; and enhance subsequent
adaptive immune responses through their released
cytokines [37].
Macrophages play a vital role in antitumor innate
response by elimination of apoptotic tumor cells in order
to obviate autoimmunity. During apoptosis, tumor cells
express special molecules at their surface (lipid phosphati-
dylserine, oxidized PS, oxidized low-density lipoprotein
and the multi-functional protein calreticulin) which are
recognized by macrophages and lead to tumor cell phago-
cytosis [38, 39]. In contrast, it has been documented that
tumor-associated macrophages type 2 (M2) are respon-
sible for tumor metastasis [40] and progression [41] by
promoting the transfer of tumor cells into the local blood
vessels [40] and inhibiting of tumor-specific T cells [41].
Tumor antigens have been classified into two categor-
ies, 1) tumor-associated antigens (TAAs) which are
expressed by more than one type of tumor cells as well
as normal tissues and, 2) tumor specific antigens (TSAs),
on the other hand, are products of random somatic
point mutations induced by physical or chemical carcin-
ogens and therefore expressed uniquely by individual tu-
mors and not by any normal tissue, representing the
only true tumor-specific antigens [42, 43].
Immune response evasion by tumor
The mechanisms that allow cancer to evade the anti-
tumor immune response are mainly divided into two
categories, intrinsic and extrinsic. Tumor intrinsic mech-
anism is achieved by immunosuppressive cytokines, vas-
cular endothelial growth factor (VEGF), indoleamine 2,3-
dioxygenase (IDO), programmed cell death ligand (PD-L),
Fas ligand (Fas-L) and Treg. Tumor extrinsic mechanism
is mediated by suppressive cells including alternatively ac-
tivated M2-like tumour-associated macrophages (TAMs),
suppressive T cells, immature APCs, plasmacytoid
dendritic cells (pDCs) and heterogeneous population of
myeloid-derived suppressor cells (MDSCs) [44].
Lung cancer evades the immune response through
multiple mechanisms. For instance, lung cancer cells go
through a slow process of immunoediting, in which pre-
cancerous cell slowly undergoes selective adaptation to
oppose immune surveillance, a phenomenon called “im-
mune sculpting” [45]. Lung cancer cells also disturb the
routine processing of their antigens by pAPC through
secretion of various proteins including STAT-3, IDO,
TGF-β, and IL-10 [46, 47]. Besides, the dense fibrotic
stroma around tumor region influences antitumor im-
munity by limiting access of T cells to tumor cells [48].
Moreover, lung cancer evade the host immune response
by down-regulation of MHC class I molecule expression,
thereby rendering any endogenous or therapeutic anti-
tumor T cell responses ineffective [49]. Finally, lung
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cancer promotes the increase of immune suppressive
cells, specifically Treg [50] and MDSC [51]. These im-
mune suppressive cells accumulate in the tumor micro-
environment, promote tumor growth, and downregulate
antitumor immune responses [50, 51].
Recently it was revealed that the immune checkpoint
molecules, specifically cytotoxic T-lymphocyte antigen-4
(CTLA-4) and programmed death-1 (PD-1), play an import-
ant role in tumor immune response evasion. CTLA-4 is a
protein receptor expressed on the surface of CTL following
their full activation. The binding between CTLA-4 and B7-1
(CD80) or B7-2 (CD86) on APCs prevents the overactivity
of T cells under normal conditions. During cancer, T cells
express a high level of CTLA-4, so that, cancer can evade
the cytotoxic effect of T cells [52, 53]. PD-1 is a surface re-
ceptor expressed on the surface of activated T cells, B cells,
NK cells, and host tissues. Binding of PD-1 with its ligand
(PD-L1) on the surface of APCs leads to the tolerance of T
cells [54, 55]. It has been documented that numerous epi-
thelial cancers express PD-L1 which leads to T-cell anergy
through binding with their PD-1 molecules [56].
Lung cancer vaccines
Over the last 15 years, numerous efforts have been made
to enhance a potent antitumor responses using vaccines
to target specific tumor-associated antigens. Although,
most studies did not reach their final goals, different
subsets analysis showed that, those vaccines could an ef-
fective strategy to treat several kinds of tumor including
lung cancer. Furthermore, numerous studies indicated
that combination of therapeutic vaccines with immune
checkpoint inhibitors may play a crucial role in the
therapy of lung cancer. Finally, it’s important to mention
that one of the most important aspect in immunotherapy
is designing vaccine that stimulate both a potent immune
response and a correlative clinical response. In the follow-
ing section, we will discuss the efficacy of therapeutic
vaccines that have been studied extensively in lung cancer.
Melanoma-associated antigen A3 (MAGE-A3) based
vaccine
Melanoma-associated antigen-A3 (MAGE-A3) is normally
presented on testes and placenta. It is also considered as a
tumor specific antigen that only expressed on the surface
of tumor cells such as melanoma, bladder, non small cell
lung carcinoma (NSCLC) and hepatocellular cancer [57].
It has been documented that tumor cells expressing
MAGE-A3 antigen are not able to present it to the helper
(CD4+) and CTLs. So that, this antigen could be used as
immunotherapeutic agent to activate an effector immune
response against tumor MAGE-A3 expressing cells [58].
In a double-blind, randomized, placebo-controlled
phase II study, 182 patients of stage IB/II NSCLC were
enrolled to receive the recombinant MAGE-A3 vaccine
(n = 122) or placebo (n = 60). The results showed that
there was no significant difference between vaccinated
patients and placebo group regarding to disease-free
interval (DFI), disease-free survival (DFS), and overall
survival (OS) (Table 1). On the other hand, it was re-
corded that after 44 months, recurrence was observed in
35 % of patients who received recombinant MAGE-A3
vaccine compared with 43 % of patients in placebo
group. Interestingly, IgG antibodies against MAGE-A3
has been detected in all MAGE-A3 vaccinated patients
which refers to the ability of this vaccine to induce a spe-
cific immune response. These results proved the efficiency
of MAGE-A3 vaccine with minimal toxicity. This study
referred that MAGE-A3 vaccine could still provide benefit
in combination with immune checkpoint inhibitors that
reverse a tumor’s immunosuppressive effects [59].
Table 1 Clinical trials of therapeutic vaccines in lung cancer
Vaccine Phase Pt No. Stages Results
MAGE-A3 II 182 IB/II DFI: (HR: 0.75, 95 % CI, 0.46 to 1.23; two-sided P = .254); DFS: (HR: 0.76; 95 % CI, 0.48
to 1.21; P = .248); OS: (HR, 0.81; 95 % CI, 0.47 to 1.40; P = .454) [59].
BLP25 II 171 IIIB/IV Median OS: 17.4 months with L-BLP25/BSC vs 13.0 months with BSC alone [68].
Subset analysis (n = 65):
Median OS: 30.6 months with L-BLP25/BSC vs 13.3 months with BSC alone [69].
III 1239 III Median OS: 25.6 months with L-BLP25 vs 22.3 months with placebo [70].
Subset analysis (patients with previous chemoradiotherapy):
Median OS: 30.8 months with L-BLP25 vs 20.6 months with placebo [70].
Belagenpumatucel-L II 75 II/IV Estimated 2-years survival: 52 % with high doses vs 20 % with low doses [75].
III 532 III/IV Median OS: 20.3 months with belagenpumatucel-L vs 17.8 months with placebo [76].
Subset analysis (patients with pretreatment radiation):
Median OS: 40.1 months with belagenpumatucel-L vs 10.3 months with placebo [76].
CIMAvax EGF II 80 IIIB/IV Median survival: 11.7 months with GAR vs 3.6 months with PAR [81].
TG4010 II 148 IIIB/IV 6-months PFS: 43.2 % with TG4010/chemotherapy vs 35.1 % with chemotherapy alone [84].
Abbreviations: DFI disease free interval, DFS disease-free survival, OS overall survival, HR hazard ratio, BSC best supportive care, PFS progression free survival, GAR
good anti-EGF antibody response, PAR poor antibody response
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To overcome the shortages of previous clinical study
(small sample size and lacking of adjuvant therapy), the
efficacy of MAGE-A3 vaccine was detected in phase III
lung cancer which enrolled 2272 patient with NSCLC.
Unfortunately, this study has been stopped in 2014 be-
cause adjuvant treatment with the MAGE-A3 immuno-
therapeutic did not increase disease-free survival
compared with placebo in patients with MAGE-A3-
positive surgically resected NSCLC [60].
MUC1 derived liposomal BLP25 vaccine
MUC1 is a glycoprotein that expressed normally at the
surface of epithelial cells in lung, stomach, intestines, eyes
and several other organs and over-expressed in colon,
breast, ovarian, lung and pancreatic cancers [61, 62]. It
consists of four domains, extracellular subunit (20 amino
acid tandem repeat domain), a small extracellular domain
subunit, a transmembrane domain and a cytoplasm tail
[62]. MUC1 supports tumor growth and metastasis
depending on its anti-adhesive features, which prevent
cell-cell adhesion [63]. The extracellular immunogenic
subunit (25 A.A.) of MUC1 combined with the nonspe-
cific adjuvant monophosphoryl lipid A and three different
lipids was combined together to prepare a therapeutic
lung cancer vaccine called liposomal BLP25 (L-BLP25,
Stimuvax) [64, 65]. In vitro experiments showed that,
stimulation of peripheral blood lymphocytes with Stimu-
vax resulted in induction of a strong MUC1-specific CD8+
T cells response [66].
In phase I; Palmer M, et al. [67], have evaluated the
safety and immunogenicity of L-BLP25 vaccine in
Patients with stage IIIB or IV NSCLC. They found that
this vaccine could be administered with minimal toxicity
and can elicit a primarily cellular immune response.
An open-label, randomized phase II trial in patients
with stage IIIB or IV NSCLC who had underwent any
first-line chemotherapy was undertaken to test the effi-
cacy of L-BLP25. 171 patients from 17 centers in Canada
and United Kingdom were recruited in this study. Pa-
tients were divided into two groups and received MUC1
liposomal vaccine combined the best supportive care
(BSC) or only BSC, respectively. The overall survival
showed a trend toward longer survival with L-BLP25
plus the BSC vs. BSC alone (median: 17.4 vs.
13.0 months) [68]. A subset analysis of patients with
stage IIIb locoregional NSCLC (n = 65) showed a trend
for improved survival in those patients treated with L-
BLP25 compared with BSC alone; median OS was 30.6
versus 13.3 months [69] (Table 1).
In phase III trials; Butts C, et al. [70] started a ran-
domized, double-blind trial called START (Stimulating
Targeted Antigenic Response To NSCLC) to detect
whether L-BLP25 vaccine could improve the survival in
patients with stage III unresectable NSCLC when given
as maintenance therapy after chemoradiation. 829 pa-
tients were received tecemotide vaccine and 410 patients
were designate as placebo on a double-blind basis. The
results showed that there was no statistically difference
in overall survival between vaccinated patients and pla-
cebo (25.6 months vs 22.3 months). Interestingly, sub-
group analysis revealed that there was a remarkable
improvement in the patients who received previous con-
current chemoradiotherapy. The median overall survival
for 538 (65 %) of the 829 patients assigned to tecemotide
was 30.8 months compared with 20.6 months for the
268 (65 %) of 410 patients assigned to placebo (Table 1).
Transforming growth factor-ßs (TGFßs) based vaccines
TGFß1, TGFß2, and TGFß3 are three highly homolo-
gous isoforms members of TGFß superfamily which also
consists of more than 30 members (activins, NODAL,
etc.) [71]. TGFß expression plays an opposite roles in
cancer formation and development. In the primary stage
of tumor, TGFß pathway induces cell cycle arrest and
apoptosis [72, 73], whereas, in the late stage it supports
tumor progression and metastasis [73, 74].
Belagenpumatucel-L vaccine
Belagenpumatucel-L (Lucanix®) vaccine aims to stimulate
immune system of NSCLC patients using genetically
modified and irradiated whole tumor cells that consist of
a TGFß2 antisense gene [75].
In a randomized, dose-variable, phase II clinical trial;
belagenpumatucel-L has been tested in 75 patients with
NSCLC (stages II-IV), patients were divided into groups
and received one of three doses (1.25, 2.5, or 5.0 × 107
cells per injection on a monthly or every other month
schedule for up to 16 injections). In the subgroup of 61
late-stage (IIIB and IV) assessable patients showed a a
partial response rate of 15 %. Importantly, patients who
vaccinated with high doses (≥25 × 106cells per injection)
showed a better OS than those who vaccinated with low
doses (12.5 × 106 cells per injection) with an estimated
2-years survival of 52 % versus 20 %, respectively
(Table 1). Moreover, a high production level of IFN-ɣ, IL-
4, and IL-6 cytokines was detected in vaccinated patients
who showed a partial responses (PR) or stable diseases (SD)
status. This vaccine also recorded an acceptable safety
profile [75].
In phase III clinical trial, 532 patients of stage III/IV
NSCLC who did not progress after platinum-based
chemotherapy were divided into two groups, 270
patients were received belagenpumatucel-L and 262 pa-
tients assigned as placebo group. This trial has not
achieved its endpoint to improve the overall survival
(20.3 months with belagenpumatucel-L vs 17.8 months
with placebo). Besides, There were no differences in PFS
between two groups (4.3 months with belagenpumatucel-L
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vs 4.0 months with placebo). Although the overall survival
was not improved, the subgroup analysis showed that pa-
tients with confirmed pretreatment radiation had a median
OS of 40.1 months with belagenpumatucel-L compared
with 10.3 months for placebo patients. More importantly,
Patients with non-adenocarcinoma who were randomized
within 12 weeks of the completion of chemotherapy had a
median OS of 19.9 months on belagenpumatucel-L, while
those who received placebo had an OS of 12.3 months
(Table 1). These data, along with a strong safety profile,
support the continued development of belagenpumatucel-L
for this indication,” the investigators concluded, in spite of
the study’s failure to meet its endpoint [76].
CIMAvax EGF vaccine
Epidermal growth factor receptor (EGFR) is a member
of receptor tyrosine kinases (RTKs) family which con-
sists of EGFR (ErbB1, HER1), ErbB2 (HER2), ErbB3
(HER3) and ErbB4 (HER4). EGFR tyrosine kinase is acti-
vated after binding with EGF and can induce a conform-
ational receptor changing by (homo or heterodimer
formation), this process is followed by substrate phos-
phorylation via activated EGFR and activation of down-
stream pathways which are responsible for cell survival
and proliferation [77]. EGFR gene mutation (overactiva-
tion) leads to transformation of normal cells to be a ma-
lignant cells. The hallmarks of this transformation are,
apoptosis suppression, cell proliferation, angiogenesis,
metastasis, tumor-induced proinflammatory and im-
munosuppressive processes [78, 79]. It has been docu-
mented that overexpression of EGFR is associated with
lung cancer [80].
CIMAvax EGF vaccine was developed by Cuban re-
searchers to treat NSCLC adult patients with stage IIIB/
IV after receiving conventional first-line chemotherapy
through enhancing the own immune system to produce
anti EGF antibodies and decrease the serum EGF. In
phase II study; 80 NSCLC patients, after finishing first-
line chemotherapy, were randomly assigned to receive
BSC or EGF vaccine. 51.3 % of vaccinated patients
showed an obvious anti-EGF antibody response (good
anti-EGF antibody response -GAR-) and in none of the
control group (poor antibody response -PAR-) (Table 1).
Furthermore, the concentration of Serum EGF was obvi-
ously decreased in 64.3 % of vaccinated patients. Inter-
estingly, the researchers found that there was a strong
relationship between survival rate and elevation of anti-
body response and decreasing of serum EGF. CIMAvax
EGF vaccine also recorded a good safety profile [81].
TG4010 vaccine
TG4010 is a therapeutic lung cancer vaccine targeting
MUC1 antigen. It consists of attenuated Ankara virus
which modified to express MUC1 and IL-2 [82]. It aims
to overcome the inhibition status of T-cell response re-
sulted by cancer-associated MUC1 [83].
In phase II clinical trial; 148 patients with stage IIIB/IV
NSCLC were divided into two groups, 74 patients received
TG4010 combined with chemotherapy (cisplatin–gemci-
tabine), other 74 patients were received chemotherapy
alone. The results revealed that, 6-month PFS was 43.2
(32/74) in the TG4010 plus chemotherapy group, and
35.1 % (26/74) in the chemotherapy alone group (Table 1).
Interestingly, PFS in patients with a normal level of acti-
vated natural killer cells (aNK), was obviously higher than
control group (58 % vs 38 %). Besides, the median OS in
patients with normal level of aNK cells was higher than
patients with high level (18 months vs 11.3 months). The
authors concluded that TG4010 could improve the effect
of chemotherapy in advanced NSCLC [84].
Immune checkpoint inhibition
Several studies indicated that immune checkpoints
blockade is a very promising in treating a variety of ma-
lignancies including lung cancer. Among these immune
checkpoint are CTLA-4, PD-1 and PD-L1. Below is a
discussion of recent progress made in immunotherapy
for lung cancer using immune checkpoint inhibitors.
Inhibition of cytotoxic T-lymphocyte-associated protein 4
(CTLA-4)
In order to recognize and eliminate tumor cells, CTLs
require two activating signals, the first signal is provided
by TAAs presented by class I molecules on pAPCs [85].
The second signal is called “costimulatory signal” which
is achieved by binding of costimulatory receptor CD28
on T cells with two costimulatory molecules, B7-1
(CD80) and B7-2 (CD86) on APCs (Fig. 3a) [86]. Once a
CTL becomes activated it expresses a fundamental im-
munosuppressive molecule called CTLA-4 on its surface
which then binds with costimulatory molecules on APCs
about 20 times more avidly than does CD28 (Fig. 3b).
The balance between activation and inactivation signals
keeps cytotoxic activity in check, while allowing T-cell
function to work in a self-limited manner [87]. It has
been documented that one of the most important tumor
immune evasion mechanisms is upregulation of CTLA-4
expression on T cells with the help of TGF-β during the
early stage of tumorigenesis. In recent years significant
progress has been made in developing of specific mono-
clonal antibodies to inhibit CTLA-4 as a potent strategy
in cancer immunotherapy (Fig. 3c) [88, 89].
CTLA-4 inhibition by ipilimumab
Ipilimumab (MDX-010) is a fully human IgG1 monoclo-
nal antibody targeting CTLA-4-mediated T-cell suppres-
sion to enhance a potent immune response against
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tumors. In double-blind, multicenter phase II clinical
trial; depending on the treatment type, NSCLC patients
(N = 204) were divided into three arms of trial, 1) control
(chemotherapy with placebo), 2) concurrent ipilimumab
(ipilimumab plus chemotherapy, then, placebo plus
chemotherapy) or 3) phased ipilimumab (placebo plus
chemotherapy, then, ipilimumab plus chemotherapy).
Patients were received treatment intravenously every
3 weeks for 18 weeks. The immune-related progression-
free survival (irPFS) was assessed as the main endpoint
besides other endpoints, progression-free survival (PFS),
best overall response rate (BORR), immune-related
BORR (irBORR), overall survival (OS), and safety [90].
It has been shown that, phased ipilimumab improved
irPFS and PFS compared with control group, the median
irPFS associated with phased ipilimumab was 5.7 months
and the PFS was 5.1 months. Whereas, low irPFS and
median PFS were seen in concurrent ipilimumab (irPFS:
5.5 months, PFS: 4.1 months), and control treatments
(irPFS: 4.6 months, PFS: 4.2 months). phased ipilimumab
also induced 32 % of irBORR compared with concurrent ipi-
limumab and control treatments (21 and 18 %, respectively).
The median OS associated with phased ipilimumab was
12.2 months versus 9.7 and 8.3 months for concurrent ipili-
mumab and control groups, respectively (Table 2). The fol-
lowing adverse events (AEs) were similar across study arms,
fatigue, alopecia, nausea, vomiting, and peripheral sensory
neuropathy. Whereas, rash, pruritus, and diarrhea, showed a
trend for increased incidence in the ipilimumab-containing
arms than in chemotherapy arm [90].
These promising results lead to “A Randomized,
Multicenter, Double-Blind, Multinational, phase III trial”
(NCT01285609) in NSCLC which started in 2014 to de-
termine whether the combination of ipilimumab and
chemotherapy could extend the life of patients with
NSCLC compared with chemotherapy alone, as well as,
detecting the PFS and OS among enrolled patients.
Results are expected to be revealed in late of 2018.
Fig. 3 T cell activation and inactivation mechanism. a upon infection the full activation of specific T cell immune response requires two signals;
binding of MHC/Ag complex on the APC (ex: DC) with T cell receptor (TCR) and interaction of B7-molecules (CD80/86) to their ligand (CD28) on
the surface of T cell. b Activated T cell expresses a surface immunosuppressive molecule called CTLA-4 which compete with CD28 molecule to
bind the B7 molecules. The balance between activation and inactivation signals keeps cytotoxic activity in check, while allowing T-cell function to
work in a self-limited manner. c Tumor cells produce a suppressive cytokine that lead to the upregulation of CTLA-4 on the surface of T cells. This
mechanism allows tumor cells to evade the cytotoxic effect of T cells
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CTLA-4 inhibition by tremelimumab
Tremelimumab (ticilimumab) is a fully human IgG2
monoclonal antibody with high affinity to CTLA-4. In
open-label phase II trial; tremelimumab was tested in 87
patients with NSCLC compared with supportive care
only following 4 cycles of chemotherapy. PFS in tremeli-
mumab treated patients was 20.9 % compared with
14.3 % in supportive care group (Table 2). The results
revealed that 20 % of patients experienced a grade 3/4
AEs, the most common being colitis [91].
In an open-label, single-arm, phase II trial; 29 patients
with advanced mesothelioma were received at least one
dose of tremelimumab. This trial did not reach its pri-
mary endpoint in which only two patients had a durable
partial response. On the other hand, a disease control
was noted in 31 % of patients with a median PFS of
6.2 months and median OS of 10.7 months (Table 2). 27
patients experienced a grade 1/2 AEs (cutaneous rash,
pruritus, colitis, or diarrhea), and 4 patients experienced
at least one grade 3/4 AEs (two gastrointestinal, one
neurological, two hepatic, and one pancreatic). The au-
thors concluded that tremelimumab could be an effect-
ive treatment strategy in previously treated patients with
advanced malignant mesothelioma [92].
Currently, tremelimumab is tested in a randomized
phase II trial for advanced mesothelioma (NCT01843374)
and in combination with other checkpoint inhibitors for
treatment of NSCLC (NCT01843374) [93].
PD-1/PDL-1 pathway
PD-1 (CD279) is a surface receptor on activated T cells,
B cells, monocytes, NK cells, and many tumor infiltrat-
ing lymphocytes (TILs). Its ligand, PD-L1 (B7-H1;
CD274) is expressed on the surface of resting T cells, B
cells, DCs, macrophages, vascular endothelial cells, and
pancreatic islet cells [94]. The binding between PD-1
and PD-L1 leads to transmitting of an inhibitory signal
into T cell which reduces cytokines production and sup-
presses T cell proliferation [95]. This pathway plays a
crucial role in protecting own body against tissue dam-
age during response to infections [96].
It has been found that PDL-1 is over expressed on
tumor cells or on non-transformed cells in the tumor
microenvironment [95] in which PD-1/PD-L1 inter-
action inhibits the proliferation, survival, and effector
function of CTL and thus induces apoptosis of TILs
(Fig. 4) [97]. Moreover, PD-L1 molecule plays an import-
ant role in differentiation of Treg and maintaining their
suppressive function. Recently, the development of anti-
PD agents has taken center stage in cancer immunother-
apeutic strategies [98].
Table 2 Results of clinical activity for immune checkpoint inhibitors in lung cancer
Target Agent/Ab type Pt No. Phase Results
CTLA-4 Ipilimumab
IgG1
204 II Phased ipilimumab: irPFS: 5.7 months; PFS: 5.1 months; Median OS: 12.2 months.
Concurrent ipilimumab: irPFS: 5.5 months; PFS: 4.1 months; Median OS: 9.7 months.
Control: irPFS: 4.6 months; PFS: 4.2 months; Median OS: 8.3 months [90].
Tremelimumab
IgG2
87 II ORR: 4.8 %; PFS: 20.9 % vs. 14.3 % with supportive care [91].
29 II Disease control: 31 % of patients, Median PFS: 6.2 months; Median OS: 10.7 months [92].
PD-1 Nivolumab
IgG4
129 I Median OS across doses: 9.9 months; Median OS: 14.9 months at 3 mg/kg vs 9.2
at 1&10 mg/kg; ORR: 3 (1 mg/kg), 24 (3 mg/kg), and 20 % (10 mg/kg). 1-year OS
rates at 3 mg/kg: 56 % [99].
117 II PR: 14.5 % of patients; Stable disease: 26 % of patients; Median duration: 6 months;
Median OS: 8.2 months; 1-year OS rates: 40.8 % [100].
582 III Median OS: 12.2 months vs 9.4 months with docetaxel; ORR: 19.2 % vs 12.4 % with
docetaxel. Median DOR: 17.1 months vs 5.6 months docetaxel [101].
Pembrolizumab
IgG4
495 I ORR: 19.4 %; Median DOR: 12.5 months; Median PFS: 3.7 Months; Median OS: 12 months [102].
PD-L1 Atezolizumab
IgG1
37 I ORR: 24 %; 24-week PFS: 48 % [106].
667 II ORR: 19 % when atezolizumab used as a first-line therapy vs 17 % when it was a second-line
or subsequent therapy [107].
277 II OS: 12.6 months with atezolizumab vs 9.7 with docetaxel; PFS: 2.7 months with atezolizumab
vs 3 months with docetaxel; OR: 14.3 with atezolizumab vs 7.2 with docetaxel [108].
BMS-936559
IgG4
75 I ORR: 10 %; Stable disease ≥24 weeks: 12 %; PFS at 24 weeks: 31 % [109].
MEDI4736
IgG1
200 I/II ORR: 16 %; Disease control rate at 12 weeks: 42 % [110].
Abbreviations: CTLA-4 cytotoxic T-lymphocyte antigen-4, PD-1 programmed death 1, PD-L1 programmed death ligand 1, irPFS immune-related progression-free
survival, PFS progression-free survival, OS, overall survival, ORR objective response rate, DOR duration of response, OR objective response
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Inhibition of PD-1 by nivolumab
Nivolumab (marketed as Opdivo) is a human monoclonal
IgG4 against PD-1. In a phase I study of NSCLC; 129 pa-
tients were treated with nivolumab every 2 weeks (doses:
1, 3, or 10 mg/kg). The median OS across doses was
9.9 months in all patients. The median OS in patients re-
ceiving nivolumab 3 mg/kg was 14.9 months compared
with 9.2 months in both the 1 and 10 mg/kg cohorts.
Across all dose levels, 1-, 2-, and 3-year survival rates were
42, 24, and 18 %, respectively. Whereas, At the 3-mg/kg
dose, 1-, 2-, and 3-year OS rates were 56, 42, and 27 %, re-
spectively. The objective response rates (ORR) by dose
were 3 (1 mg/kg), 24 (3 mg/kg), and 20 % (10 mg/kg).
Among 22 patients (17 %) with objective responses, esti-
mated median response duration was 17 months with
20.6 months of PFS. The most common treatment-related
AEs were fatigue, decreased appetite, and diarrhea.
Besides, treatment-related select AEs of any grade were
observed in 41 % of patients and the most common in-
cluded skin, GI, and pulmonary events. The authors con-
cluded that nivolumab can induce a durable response and
prolong the survival rate in patients with NSCLC [99].
In a phase II, single arm trial, was performed at 27 sites
in France, Germany, Italy, and USA. 117 patients with re-
fractory stage IIIB or stage IV squamous NSCLC were ad-
ministered by intravenous nivolumab (3 mg/kg) every
2 weeks until progression or unacceptable toxic effects.
Nivolumab treatment induced a partial response in 14.5 %
of patients, including two patients with nontarget baseline
central nervous system metastases, with a reduction in
tumor burden of at least 50 % for 65 % of these respond-
ing patients. Furthermore, nivolumab treatment resulted
in stable disease in 30 (26 %) patients, with a median dur-
ation of 6 months. Median overall survival was 8.2 months
and overall survival at 1 year was 40.8 % (Table 2). More
importantly, the results indicated that nivolumab had
activity in patients with PD-L1–negative and positive
tumors. Nivolumab also exhibited a manageable safety
profile [100].
In phase III trial; 582 previously treated patients with
advanced or metastatic squamous cell NSCLC were
divided randomly into two groups, 292 patients were
vaccinated subcutaneously with nivolumab every 2
weeks 3 mg/kg, other 290 patients were treated with
standard chemotherapy (docetaxel/75 mg/m2/every 3
weeks). The OS of patients who treated with nivolumab
was 12.2 months versus 9.4 months in patients who
treated with chemotherapy. Moreover, nivolumab im-
proved the ORR compared with docetaxel (19.2 % vs
12.4 %). The median duration of response induced by
nivolumab was higher than that in docetaxel treated pa-
tients (17.1 months vs 5.6 months) (Table 2). Treatment-
related AEs were low in severity with nivolumab and were
less frequent with nivolumab than with docetaxel. The
most frequently reported treatment-related AEs of any
grade in the nivolumab group were fatigue, nausea,
decreased appetite, and asthenia. Moreover, treatment-
related serious AEs were less frequent in the nivolumab
group than in the docetaxel group. The following
treatment-related select AEs of any grade showed a trend
for increased incidence in the nivolumab group, were rash,
pruritus, erythema, diarrhea, hypothyroidis, increased
alanine aminotransferase level, increased aspartate amino-
transferase level, and pneumonitis. Based on these signifi-
cant results, the FDA approved nivolumab (Opdivo®), made
by Bristol-Myers Squibb (BMS), for treatment of advanced
squamous NSCLC patients who have stopped responding
to chemotherapy [101].
Inhibition of PD-1 by pembrolizumab
Pembrolizumab (also called: MK-3475, Keytruda) is a
humanized antibody against PD-1 receptor. In phase I
trial, 495 patients with advanced NSCLC were treated
Fig. 4 The mechanism of PD-1/PD-L1 pathway. Programmed cell death-1 (PD-1) receptor is expressed on the surface of activated T cells, B cells,
monocytes, NK cells, and many TILs. Its ligand, PD-L1 is expressed on the surface of resting T cells, B cells, dendritic cells, macrophages, vascular
endothelial cells, and pancreatic islet cells. The binding between PD-1 and PD-L1 leads to transmitting of an inhibitory signal into the T cell which
reduces cytokine production and suppresses T-cell proliferation. PDL-1 is over expressed on tumor cells by which PD-1/PD-L1 interaction inhibits
the proliferation, survival, and effector function of CTL and thus induces apoptosis of tumor-infiltrating T cells
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with pembrolizumab every 2 weeks or every 3 weeks
with two different doses, 2 mg/Kg or 10 mg/Kg. Among
patients, 182 were assessed as a training group and 313
as a validation group. Interestingly, antitumor activity
were detected in treated patients without a serious side
effects, ORR was 19.4 %, and the median duration of re-
sponse was 12.5 months. The median duration of PFS
was 3.7 months, and the median duration of OS was
12.0 months (Table 2). Pembrolizumab had an accept-
able side-effect profile by which the most common
treatment-related AEs were fatigue, pruritus, and de-
creased appetite. The only treatment-related AEs of an
inflammatory or immune-mediated nature that occurred
in more than 2 % of patients were infusion-related reac-
tions, hypothyroidism, and pneumonitis [102].
Other primary data showed that combination of nivo-
lumab and pembrolizumab could be an effective strategy
to treat NSCLC patients. In September 2015, The FDA
granted and approved pembrolizumab to treat patients
with advanced, PD-L1-positive NSCLC [103, 104].
Inhibition of PD-L1 by Atezolizumab
Atezolizumab (also called: MPDL3280A) is a humanized
IgG1 antibody that targets PD-L1 [105]. The results of
phase I clinical trial in previously treated NSCLC patients
showed a 24 of ORR and 48 % of 24 weeks PFS.
Biomarker data analysis proved a correlation between PD-
L1 status and efficacy of atezolizumab [106] (Table 2).
Phase II clinical trials were performed in two different
studies, the first single-arm, phase II (BIRCH) study en-
rolled 667 patients with stage IIIB/IV or recurrent
NSCLC to receive a treatment with atezolizumab as the
first line of therapy or a subsequent therapy. 19 % of
ORR was recorded when atezolizumab used as a first-
line therapy compared with 17 % when it was a second-
line or subsequent therapy (Table 2). The most com-
monly reported AEs were fatigue and nausea. Besides,
the authors noted that the efficacy of Atezolizumab is
associated with the high level of PD-L1 ligand [107].
In the second phase II, multicentre, open-label (POP-
LAR) trial, two groups of patients with NSCLC were
assessed to detect the efficacy of atezolizumab, the first
group consisted of 142 patients and received 1200 mg of
atezolizumab once every 3 weeks, the second group
assessed 135 patients and treated with 75 mg/m2 of do-
cetaxel once every 3 weeks. The OS was 12.6 months in
patients who received atezolizumab, compared with
9.7 months in those who received docetaxel. PFS was
similar between groups (2 · 7 months with atezolizumab
vs 3 months with docetaxel). Importantly, OR with ate-
zolizumab were durable, with a median duration of
14.3 months versus 7.2 months for docetaxel (Table 2).
Furthermore, it has been noted that increasing improve-
ment of OS was associated with high expression of PD-
L1. A good safety profile and toleration were recorded in
atezolizumab treated patients compared with those who
treated with docetaxel. 40 % of patients in the atezolizu-
mab group experienced grade 3–4 adverse events versus
53 % in the docetaxel group. The most common
atezolizumab-related grade 3 AEs were pneumonia and
increased aspartate aminotransferase. No atezolizumab-
related grade 4 AEs were reported. This study also con-
firmed the results of BIRCH trial results which showed
that atezolizumab has a good efficacy in patients with
the highest levels of PD-L1 [108].
In February 2015, the FDA approved atezolizumab to
treat PD-L1–positive NSCLC patients who has not showed
a response to chemotherapy. The randomized phase III trial
for this indication is in-progress (NCT02486718).
Inhibition of PD-L1 by BMS-936559
BMS-936559 is a human IgG4 monoclonal antibody
with high affinity to PDL1. In a multicenter phase I trial;
75 patients with NSCLC were received BMS-936559
every 2 weeks with escalating doses for a maximum of 2
years. The results showed that 10 of treated patients
achieved a partial response, and 12 % had stable disease
for at least 24 weeks. PFS at 24 weeks was 31 %. How-
ever, further results from this study are pending. Drug-
related AEs were observed in 39 % of patients and in-
cluded rash, hypothyroidism, hepatitis, and one case
each of sarcoidosis, endophthalmitis, diabetes mellitus,
and myasthenia gravis [109].
Inhibition of PD-L1 by MEDI4736
MEDI4736 (Durvalumab) is an IgG1 antagonist anti-
body, that blocks PD-L1 binding to PD-1 and CD80, de-
signed with a mutated FC domain to prevent antibody-
dependent cell mediated cytotoxicity (ADCC). In phase
I/II, multicenter, open-label study, 228 patients (126
non-squamous and 102 squamous histology) were
enrolled to evaluates the safety and clinical activity of
durvalumab. The results showed that, of 200 evaluable
treated patients the ORR was 16 % (27 % in PD-L1+),
and disease control rate at 12 weeks was 42 %. The ORR
in 88 patients with squamous NSCLC was 21 % whereas,
in 112 with non-squamous NSCLC, the ORR was 13 %
(Table 2). The most frequently Drug-related AEs were
fatigue, decreased appetite and nausea [110].
Based on encouraging activity in early trials, durvalumab
is currently being evaluated in several phase III trials in
NSCLC such as ARCTIC, a global, phase III, randomized,
open-label multicenter study (NCT02352948) which aims
to asses the 1) safety and clinical activity of durvalumab
versus standard of care (SoC) in patients with PD-L1+
tumors; and 2) the combination of durvalumab plus tre-
melimumab or either agent as monotherapy versus SoC in
patients with PD-L1− tumors [111].
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Conclusions
In the last few years there has been a growing interest in
cancer immunotherapy due to its promising results in
achieving significance and durable treatments responses
with minimal manageable toxicity. Cancer immunother-
apy has many advantages over chemotherapy or radio-
therapy. In this regard, immunotherapy is receiving a
particular interest due to its favorable benefits, low risk
ratio and durable activity. It also showed a significant
advantage by controlling tumor growth after patients
stop responding to the standard treatments. One of the
most important future directions in cancer immunother-
apy is identifying predictive markers which can predict
the antitumor effect and survival benefit before the im-
plementation of immunotherapies. Combination therapy
is another important approach in tumor therapy. Further
investigations are needed to evaluate the role of combin-
ation the immunotherapeutic agents with one another
and with chemotherapy, targeted therapy or other treat-
ment options to treat cancers.
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